@LWebb![https://hotcopper.com.au/data/attachments/3916/3916172-c08d1dbd92bf58c8d7aea394eea1ff6d.jpg](https://hotcopper.com.au/data/attachments/3916/3916172-c08d1dbd92bf58c8d7aea394eea1ff6d.jpg)
and of course the great thing about the individual drugs used in IHLs proprietary 42X is that they both carry individual
FDA approval for treatment indications in they're own right:Acetazolamide approved for the treatment of glaucoma / interocular pressure
Dronabinol approved in the treatment of anorexia nervosa and Acquired Immune Deficiency Syndrome
'Following on from the trial, IHL has now commenced preparation of a pre-Investigational New Drug (IND) meeting package “and is targeting a pre-IND meeting with the U.S. Food and Drug Administration (FDA) in Q1 2022”, Incannex said.
looking forward to that pre IND submission / outcome
2022 appears to be shaping up as 'the year' for Incannex